癃闭舒胶囊辅助治疗前列腺增生患者对白介素10、肿瘤坏死因子影响

Effect of Longbishu Capsule on Serum IL-10 and TNF-α in the Treatment of Benign Prostatic Hyperplasia

目的:探讨癃闭舒胶囊辅助治疗前列腺增生患者对白介素10、肿瘤坏死因子的影响。方法:选取我院2015年3月—2016年6月收治的符合纳入标准且诊断为前列腺增生患者94例,按随机数字表法分为对照组和研究组,分别为47例,对照组予以常规治疗方案,研究组在西医常规治疗方案上予以癃闭舒胶囊治疗,两组共治疗3个月为1个疗程,采血测定血清炎症因子指标,观察并记录中医证候积分及临床症状、体征变化,同时对比临床疗效及并发症。结果:与治疗前比较,两组患者治疗后血清TNF-α、IL-6、IL-17含量降低,IL-10含量升高,治疗后夜尿频多、排尿困难、排尿无力、腰膝酸软等积分降低,治疗后前列腺体积、IPSS、残余尿量降低,最大尿流速升高(P<0.05);与对照组比较,研究组患者治疗后血清TNF-α、IL-6、IL-17含量较低,IL-10含量较高,治疗后夜尿频多、排尿困难、排尿无力、腰膝酸软等积分较低,治疗后前列腺体积、IPSS、残余尿量较低,最大尿流速较高(P<0.05);对照组有效率74.47%与研究组有效率91.49%数据对比,研究组高于对照组(P<0.05);所有患者均获得随访,无病例脱落现象,对照组不良率12.77%与研究组不良率14.89%数据对比,无差异(P>0.05)。结论:癃闭舒胶囊辅助治疗前列腺增生疗效确切,降低炎症因子,改善临床症状、体征,安全性高。

Objective： To investigate the effect of Longbishu Capsule on serum IL-10 and TNF-ot in the treatment of benign prostatic hyperplasia. Methods ： 94 cases of benign prostatic hyperplasia patients in our hospital from March 2015 to June 2016 were selected and randomly divided into study group and control group, 47 cases each. Control group received routine treatment, the study group received more with Longbishu Capsule, and 2 groups were treated for 3 months, the concentration of serum inflammatory factor index, the symptom scores and the changes of clinical symptoms and signs, and the clinical effect and complications were compared before and after the treatment. Results ： Compared with before treatment, levels of serum TNF-a, IL-6 and IL-17 decreased after treatment in 2 groups, levels of IL-10 content increased, scores of nocturia, dysuria, micturition weakness and soreness and weakness of waist and knees decreased, IPSS, prostate volume, residual urine volume decreased after treatment, the maximum flow rate increased （ P〈0.05 ）, compared with the control group, levels of serum TNF- ot , IL-6 and IL-17 in the study group were lower, levels of IL-10 was higher, scores of nocturia, dysuria, micturition weakness and soreness and weakness of waist and knees were lower, scores of IPSS, prostate volume, residual urine volume were lower, the maximum flow rate was higher （ P〈0.05 ）. The effective rate in the control group （ 74.47% ） was lower than the study group （ 91.49% ） （ P〈0.05 ）. All patients were followed up, no case was falling, the adverse rate in the control group was 12.77%, the adverse rate in the study group was 14.89%, no difference （ P〉0.05 ）. Conclusion ： Longbishu Capsule in the treatment of benign prostatic hyperplasia was effective, it can reduce inflammation, improve the clinical symptoms and signs of high security.